Company intelligence / Profile preview

Angalpharma

China

Ownership: Private
Development stage: Other

Overview

CPI-818, an ITK inhibitor, has been approved by FDA to enter Phase III clinical trials for relapsed/refractory peripheral T cell lymphoma with preliminary results presented at major conferences. CPI-006 monotherapy for non-small cell lung cancer has achieved impressive efficacy data in combination studies with pembrolizumab. Ciforadenant showed activity in advanced refractory renal cell cancer in Phase I/Ib trials.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Kidney Cancer Research Consortium

Beyond the preview

Go deeper on Angalpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angalpharma.

Explore the full profile